3rd International HIV/Viral Hepatitis Co-Infection Meeting
HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access

17 July 2016, Durban, South Africa

The 3rd International HIV/Viral Hepatitis Co-Infection Meeting, hosted by the International AIDS Society (IAS), took place just prior to the 21st International AIDS Conference (AIDS 2016) and was held on 17 July, 2016 in Durban, South Africa (Durban ICC, Hall 2D/E, SR8).

The recent development of highly effective antiviral therapy for HBV and HCV provides the opportunity to counter the rising burden of chronic liver disease among people living with HIV. Global antiretroviral therapy scale-up should limit HBV‐related liver disease, through dual antiviral activity. Furthermore, development of antiretroviral therapy delivery infrastructure should enhance implementation of interferon-free DAA regimens for HCV once available. The focus of the meeting will be to identify challenges and opportunities for increasing the diagnosis and treatment of viral hepatitis in HIV infected persons, particularly in low and middle-income settings.

The 3rd International HIV/Viral Hepatitis Co-Infection Meeting fills a void in the landscape of meetings providing a unique opportunity for industry, academic, community and governmental stakeholders to interact and develop constructive solutions together that can support equitable access to modern therapeutics while maintaining sustainable innovation. The conference will provide research-based evidence to demonstrate the value of these curative therapies and will engage policy makers towards creating an environment that supports their wider therapeutic access nationally and internationally.

Meeting objectives

  1. To review the latest therapeutic developments in viral hepatitis B and C 
  2. To identify challenges and successes in scaling up diagnosis, screening, antiviral treatment and prevention of viral hepatitis in HIV co-infected persons
  3. To identify how to optimize outcomes and costs to achieve sustainable and equitable access to these therapies globally
  4. To learn from successful models, such as novel voluntary licensing agreements and map a path toward scaling up of viral hepatitis treatment programmes in low-, middle- and high-income settings
  5. To advance the agenda for viral hepatitis eradication by assembling key stakeholders for a face-to-face discussion of major barriers and solutions.

Organizing Committee

Marina Klein, McGill University, CIHR Canadian HIV Trials Network (CTN)Montreal, Canada
Wendy Spearman, University of Cape TownCape Town, South Africa

Monique Andersson, Stellenbosch University, Faculty of Health SciencesStellenbosch, South Africa
Isabelle Andrieux-Meyer, MSF Geneva, Switzerland
Anchalee Avihingsanon, HIV-NAT Bangkok, Thailand
Sanjay Bhagani, Royal Free Hospital London, UK
Christoph Boesecke, University of Bonn Bonn, Germany
Laurent Castera, Hôpital Beaujon Paris, France
Curtis Cooper, CIHR Canadian HIV Trials Network (CTN)Ottawa, Canada
Greg Dore, Kirby Institute, University of New South Wales Sydney, Australia
Jordan Feld, University of Toronto Toronto, Canada
Karine Lacombe, Hôpital Saint-Antoine Paris, France
Gail Matthews, Kirby Institute, University of New South Wales Sydney, Australia
Sébastien Morin, International AIDS SocietyGeneva, Switzerland
Marion Peters, University of California San Francisco, USA
Jürgen Rockstroh, University of Bonn Bonn, Germany
Mark Sulkowski, Viral Hepatitis Center, John Hopkins Baltimore, USA
Tracy Swan, MSF Access Campaign New York, USA

Meeting material

  • Related documents
  • Presentations
  • Posters
  • Multimedia

Welcome and introduction

Welcome and introduction
Wendy Spearman


Hepatitis B topics

HBV-HIV co-infection: Epidemiology, vaccine and treatment coverage
Mark Sonderup


Monique Andersson

HBV resistance and escape mutants
Anders Boyd


Curing HBV: How close are we?
Patrick Kennedy

Clinical case discussions: Challenges in HBV management in resource-limited settings

HCC screening and management
Patrick Kennedy

Children and adolescents
Tammy Meyers


Hepatitis C topics - HCV epidemiology: The knowns and the unknowns

HCV in PWID in Africa: A hidden epidemic
Niklas Luhmann


Current trends worldwide: Implications for elimination
Margaret Hellard


Hepatitis C topics - HCV treatment update: A moving target

Role of resistance and resistance testing in managing HCV
Jürgen Rockstroh


Is a pan-genotypic therapy ready for prime time?


Financing and the scale up of HCV treatments: Entry of generics
Sunil Solomon


Medicines Patent Pool
Greg Perry


New tools, new technologies

Screening for viral hepatitis: Diagnostics (HBV and HCV)
Diana Hardie


Screening for viral hepatitis: Liver disease
Wendy Spearman


WHO Diagnostic Guidelines
Philippa Easterbrook

Panel discussion — Accessing antivirals: Overcoming remaining challenges

Opening overview and community perspective
Isabelle Andrieux-Meyer


Closing remarks
Marina Klein (presented by Jürgen Rockstroh)


Topic: HBV Epidemiology and Outcomes


Higher mortality in HIV-HBV co-infected persons with elevated HBV replication in the Temprano Trial
TM.G. Kouamé, R. Moh, A. Boyd, A. Badjé, D. Gabillard, J.B. N'takpé, S. Maylin, S.P. Eholié, X. Anglaret, C. Danel

The effect of HIV infection on the age at presentation of HBV-driven hepatocellular carcinoma in South Africa
TT. Maponga, H. Vermeulen, B. Robertson, S. Burmeister, W. Preiser, M. Kew, M. Andersson

Impact of antiretroviral therapy on liver stiffness among Zambian adults with HIV-HBV co-infection and HIV mono-infection
M. Vinikoor, E. Sinkala, R. Chilengi, L. Mulenga, B. Chi, Z. Zyambo, C. Hoffmann, M.-A. Davies, TM. Egger, G. Wandeler

Response to Truvada based cART in HIV/HBV co-infected patients in Botswana
TM. Anderson, S. Gaseitsiwe, S. Moyo, K.P. Thami, T. Mohammed, D. Setlhare, T.K. Sebunya, E.A. Powell, J. Makhema, J.T. Blackard, R. Marlink, M. Essex, R.M. Musonda

Improved liver fibrosis scores in treated HBV/HIV co-infected patients in South Africa despite persistent immune dysregulation
TT. Maponga, M. Andersson, J. Taaljaard, C.J. Van Rensburg, W. Preiser, R. Glashoff

Topic: HCV Epidemiology and Natural History


Effect of the timing of hepatitis C virus infection, relative to HIV seroconversion on CD4 T cell and HIV RNA evolution among HIV-positive MSM
TD. van Santen, J. van der Helm, G. Touloumi, N. Pantazis, R. Muga, B. Bartmeyer, J. Gill, E. Sanders, A. Kelleher, R. Zangerle, C. Béguelin, K. Porter, M. Prins, R. Geskus

Hepatitis C prevalence, viral diversity and severity of liver disease in HIV patients in Phnom Penh, Cambodia
TA. De Weggheleire, S. An, I. De Baetselier, S. Teav, V. So, S. Sea, S. Ros, S. Thai, S. Francque, L. Lynen

Extremely low hepatitis C antibody prevalence among high-risk, HIV-positive and HIV-negative men who have sex with men and transgender women from community-based organizations in Thailand
TV. Sapsirisavat, A. Avihingsanon, D. Trachunthong, S. Kerr, J. Jantarapakde, S. Pengnonyang, S. Jitjang, R. Janamnuaysook, P. Mingkwanrungrueng, J. Ohata, A. Sohn, A. Katz, N. Phanuphak

Topic: HCV Testing, Monitoring and Management


Development and validation of a risk score to assist testing for acute HCV infection in HIV-infected MSM
A.M. Newsum, I.G. Stolte, J.T.M. van der Meer, J. Schinkel, M. van der Valk, J.W. Vanhommerig, A. Buvé, M. Danta, A. Hogewoning, M. Prins

Ledipasivr/Sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection
M. Nelson, S. Bhagani, R.H. Hyland, C. Yun, M. Mertens, A. Jackson, W. Zheng, D.M. Brainard, J.G. Mchutchinson, P. Ingliz, T. Lutz, J.K. Rockstroh

Retreatment of HCV/HIV co-infected patients who failed 12 weeks of LDV/SOF
A. Luetkemeyer, C. Cooper, S. Naggie, M. Saag, D. Dieterich, M. Sulkowski, S. Naik, M. Natha, J. Yang, L. Stamm, H. Dvory-Sobol, I. Walker, J. McHutchison

Non-invasive serum markers suggest benefit for early ART initiation on liver fibrosis progression within the START study
G. Matthews, J. Neuhaus, J. Rockstroh, L. Peters, F. Gordin, A. Arenas-Pinto, C. Emerson, K. Marks, J. Hidalgo, R. Castro, C. Stephan, N. Kumarasamy, S. Emery

Telaprevir containing triple therapy in acute HCV co-infection: the CHAT study
C. Boesecke, G.J. Singh, S. Scholten, T. Lutz, A. Baumgarten, S. Schneeweiss, A. Trein, M. Rausch, P. Ingiliz, J.K. Rockstroh, M. Nelson

SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies
M. Sulkowski, K. Agarwal, K. Patel, D. Samuel, M. Bourlière, Z. Younes, T. Morgan, S. Strasser, B. Leggett, S. Naik, B. Collins, M. Natha, L. Liu, X. Ding, J. Mcnally, A. Osinusi, D.M. Brainard, J. McHutchison, N. Afdhal, I. Walker, N. Brau

Topic: HCV Treatment Access


Treatment scale-up in Australia to achieve global hepatitis C virus incidence and mortality elimination targets: a cost-effectiveness model
M. Hellard, N. Scott, E. Mcbryde, A. Thompson, J. Doyle

Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access
D. Gotham, M. Barber, J. Fortunak, A. Pozniak, A. Hill

Exposure to various combinations of Harm reduction strategies in relation to HIV and HCV incidences among PWID in Montreal, Canada
J. Bruneau, D. Jutras-Aswad, G. Zang, É. Roy

Increasing HCV Access through Clinical Education: Medical Provider Knowledge and Practice Change Intentions
N. Harris, T. Wilder, K. McKinnon, S.H. Kim, A. Urbina

Community engagement in universal access to DAA hepatitis C treatment: the Portuguese case
D. Simões, R. Freitas, B. dos Santos, R. Fuertes, L. Mendão

Photo gallery

View the photos of the meeting here